Fusion protein · Inhibitor of Vascular endothelial growth factor-A (VEGFA) and Placental growth factor (PGF) · developed by Regeneron Pharmaceuticals
ApprovedFDA, Nov 2011
What is ABP 938?
ABP 938 (Pavblu, aflibercept-ayyh) is a biosimilar version of aflibercept, a soluble decoy receptor fusion protein that binds VEGF-A and PlGF and blocks their activation of VEGF receptors on endothelial cells. It is studied in neovascular age-related macular degeneration.
Summary written with AI from the sources listed at the end of this page.
Macular Edema Following Retinal Vein Occlusion (Pavblu)
Diabetic Macular Edema (Pavblu)
Diabetic Retinopathy (Pavblu)
From the indications section of the FDA label (version of May 10, 2026). Read the full label for the exact wording, limitations and safety information.
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.